SR. NO. | INDEX | PAGE NO.
--- | --- | ---
5.1 | Evaluation of Efficacy and Safety of Pitavastatin with Atorvastatin in hyperlipidemic patients | 120
5.1.1 | Baseline Characteristics | 120
5.1.2 | Efficacy | 120
5.1.3 | Safety | 120
5.2 | Evaluation of Safety and Efficacy of Bivalirudin (antithrombin agent) with Heparin as an adjunct therapy in moderate to high risk IHD patients presenting with ACS and undergoing PCI | 125
5.2.1 | Baseline Characteristics | 125
5.2.2 | Angiographic & lesion Characteristics | 125
5.2.3 | Percutaneous Coronary Intervention details | 125
5.2.4 | Antithrombin therapy & coagulation cascades: | 126
5.2.5 | Assessment of blood flow | 126
5.2.6 | Clinical outcomes | 127
5.3 | Evaluation of Safety and Efficacy of Abciximab (GP IIb/IIIa inhibitor) with standard therapy in moderate to high risk IHD patients presenting with ACS and undergoing PCI | 133
5.3.1 | Baseline Characteristics | 133
5.3.2 | Patient Disposition | 133
5.3.3 | Electrocardiography findings | 133
5.3.4 | Hemodynamic and pathologic observations post procedure | 133
5.3.5 | Clinical Outcome | 134
5.4 | Evaluation of Safety and Efficacy of Aspiration Catheter followed by Conventional stenting with Conventional stenting alone in IHD patients presenting with AMI and undergoing PCI | 140
5.4.1 | Baseline Characteristics | 140
5.4.2 | Angiographic & lesion Characteristics | 140
5.4.3 | Percutaneous Coronary Intervention details | 140
5.4.4 | Aspiration catheter | 141
5.4.5 | Thrombus load | 141
5.4.6 | Assessment of blood flow | 141
5.4.7 | Rate of ST segment resolution | 142
5.4.8 | Periprocedural Events | 142
5.4.9 | Major Adverse Cardiac Events | 142
6.0 | DISCUSSION | 149-157
7.0 | CONCLUSIONS | 158
8.0 | REFERENCES | 159-192
9.0 | ANNEXURES | 193-204
Annexure I: Index | 193
Annexure II: Figure and Table legends | 198
Annexure III: List of Clinical Studies | 201
Annexure IV: List of abbreviations | 204